newsfilter
← Latest News
GlobeNewswire·

Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2026

  • Aligos Therapeutics presented positive data from five studies at the AASLD The Liver Meeting 2026 in Denver, CO, held November 5–9, 2026.
  • Pevifoscorvir sodium demonstrated reduced pro-inflammatory cytokine expression in HBeAg+ patients after 96 weeks of monotherapy, with increases observed during subsequent entecavir follow-up.
  • Preclinical data showed ALG-001075, the active parent of pevifoscorvir sodium, inhibited relaxed circular DNA and double-stranded linear DNA formation more potently than tenofovir disoproxil fumarate or entecavir.
  • ALG-170675, a next-generation HBV antisense oligonucleotide with dual RNase H and TLR8 agonist activities, showed deeper HBsAg knockdown than bepirovirsen in an AAV-HBV mouse model.
  • ALG-170675 has advanced to Phase 1 clinical studies in China in partnership with Amoytop.
  • In vitro data indicated that ASO ALG-215007 potently inhibited hepatitis delta virus replication across multiple cellular systems.
  • Five specific presentation abstracts detailing these findings were scheduled for November 7–8, 2026, during the conference sessions.
  • Aligos Therapeutics remains a clinical stage company focused on developing best-in-class therapies for liver and viral diseases under the NASDAQ ticker ALGS.